EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Multizentrische StudieOpen Access · CC BY-NC 4.0

Phase Ib study of anti-PD-L1 monoclonal antibody socazolimab in combination with nab-paclitaxel as first-line therapy for advanced urothelial carcinoma

Bixia Tang iD, Jun Xiao, Zhihong Chi, Rong Duan, Chuanliang Cui, Lu Si iD, Yixun Liu, Xuechun Hu, Zhi Liu, Ping Xiang, Siming Li, Xieqiao Yan und 8 weitere

The Oncologist · 2025

DOI: 10.1093/oncolo/oyae260 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift The Oncologist, 2025. Verfasst von Bixia Tang und 19 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Melanoma and Soft Tissue Sarcoma, Peking U…. Hauptthemen laut MEDLINE: Albumins, Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Transitional Cell. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Oncology Pharmaceutical Limited.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

PD-1/PD-L1 immune checkpoint inhibitors (ICIs) have demonstrated activity in the post-platinum and platinum-ineligible settings for advanced urothelial carcinoma (aUC). As only around 50% of patients with aUC can tolerate platinum-containing treatment, treatments combining first-line ICIs with non-platinum drugs are urgently needed. Therefore, we assessed the safety and efficacy of the anti-PD-L1 monoclonal antibody Socazolimab in combination with nab-paclitaxel as first-line therapy in aUC (NCT04603846).

Methods

This was a multi-center, single-arm, phase Ib study that enrolled patients with treatment-naive aUC. Patients received Socazolimab (5 mg/kg) and nab-paclitaxel (260 mg/m2) Q3w. The primary endpoint was safety and tolerability of the combination regimen. Second endpoints were the objective response rate (ORR) and progression-free survival.

Results

Between September, 2020 and September, 2021, 20 patients with urothelial carcinoma were enrolled, arising from renal pelvis (5), bladder (8), and ureter (7). After a median follow-up of 17 months, the median number of treatment cycles was 12. No patients had dose limiting toxicity. All patients had treatment-related adverse events (TRAEs), most of which were grade 1 or 2. The common TRAEs (≥20%) were peripheral neurotoxicity, alopecia, rash, increased ALT, weight loss, weakness, pruritus, increased AST, increased γGT, increased ALP, neutropenia, emesis, and anorexia. Nine patients (45%) developed grade 3 TRAEs including peripheral neurotoxicity (30.0%), increased ALT (10.0%), and increased γGT (5.0%). Two patients (10%) discontinued treatment because of grade 3 mouth ulcer (n = 1) and grade 2 lung fibrosis (n = 1). No grade 4-5 TRAEs were observed. Among the 17 patients who had received at least one tumor assessment, ORR was 58.8% (95% CI, 32.9%-81.6%) and the median progression-free survival was 8.3 months (95% CI, 5.2-19.5). The median duration of response was 13.3 months (95% CI, 2.0-20.1), and the overall survival was 19.5 months (95% CI, 11.2-not reached).

Conclusion

Socazolimab combined with nab-paclitaxel has shown good safety and promising antitumor activity as first-line therapy in patients with advanced urothelial carcinoma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AlbuminsAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Transitional CellPaclitaxelUrologic NeoplasmsAgedAged, 80 and overFemaleHumansMaleMiddle AgedB7-H1 AntigenUrinary Bladder Neoplasms

Stichwörter der Autor:innen

advanced urothelial carcinomaanti-PD-L1 antibodychemoimmunotherapy combinationfirst-linenab-paclitaxelsocazolimab

Substanzen

130-nm albumin-bound paclitaxelAlbuminsAntibodies, Monoclonal, HumanizedB7-H1 AntigenCD274 protein, humanPaclitaxel

Autor:innen und Institutionen

  • Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Melanoma and Soft Tissue Sarcoma, Peking University Cancer Hospital & Institute, Beijing, People's Republic of C…
  • Department of Urology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, People's Republic of China.
  • Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Genitourinary Oncology, Peking University Cancer Hospital & Institute, Beijing, People's Republic of China.
  • Zhaoke (Guangzhou) Oncology Pharmaceutical Limited, Guangzhou 511400, People's Republic of China.

ORCID-Profile: Bixia Tang, Lu Si, Li Zhou, Xinan Sheng

Förderung

  • Oncology Pharmaceutical Limited

Zitieren

APA

Tang, B., Xiao, J., Chi, Z., Duan, R., Cui, C., Si, L., Liu, Y., Hu, X., Liu, Z., Xiang, P., Li, S., Yan, X., Zhou, L., Li, J., Li, Y., Yu, X., Dai, X., Li, X., Guo, J., & Sheng, X. (2025). Phase Ib study of anti-PD-L1 monoclonal antibody socazolimab in combination with nab-paclitaxel as first-line therapy for advanced urothelial carcinoma. The Oncologist. https://doi.org/10.1093/oncolo/oyae260

Vancouver

Tang B, Xiao J, Chi Z, Duan R, Cui C, Si L, et al. Phase Ib study of anti-PD-L1 monoclonal antibody socazolimab in combination with nab-paclitaxel as first-line therapy for advanced urothelial carcinoma. The Oncologist. 2025. doi:10.1093/oncolo/oyae260

BibTeX
@article{Tang2025,
  author = {Tang, Bixia and Xiao, Jun and Chi, Zhihong and Duan, Rong and Cui, Chuanliang and Si, Lu and Liu, Yixun and Hu, Xuechun and Liu, Zhi and Xiang, Ping and Li, Siming and Yan, Xieqiao and Zhou, Li and Li, Juan and Li, Yujie and Yu, Xiaohui and Dai, Xiangrong and Li, Xiaoyi and Guo, Jun and Sheng, Xinan},
  title = {Phase Ib study of anti-PD-L1 monoclonal antibody socazolimab in combination with nab-paclitaxel as first-line therapy for advanced urothelial carcinoma},
  journal = {The Oncologist},
  year = {2025},
  doi = {10.1093/oncolo/oyae260}
}
Kostenlos starten →